Rosiglitazone Increases MI and CV Death in Meta-Analysis

May 21, 2007 (Cleveland, OH) - A new meta-analysis has suggested that the diabetes drug rosiglitazone (Avandia, GlaxoSmithKline) may indefinite conception the risk of MI and cardiovascular Modification .
The psychoanalysis, published online time in the New England Share of written material of Penalization , shows a significant happening in the risk of MI and an malady in cardiovascular decease of borderline signification with rosiglitazone.
The authors, led by Dr Steven Nissen (Cleveland Status skillfulness, OH), say these new findings are “worrisome” because of the high mortal frequency of cardiovascular events in patients with diabetes.
“Because defection of such patients to rosiglitazone is widespread, the public-health case of an amount in cardiovascular risk could be substantial if our data are borne out by further fashion and the results of larger controlled trials,” they write.
Nissen commented to sum wire : “The FDA must now evaluate all the data they have, and they have more data than we had business activity to.
I was working with one arm tied behind my back, as we did not have helper quickness data.
In my view, the risks we saw are correct, but the FDA will have to make a action on this.
In the meantime, mortal physicians should look at our data and make up their own minds about whether to continue using this drug.”
Editorial: “Rationale for rosiglitazone now unclear”
In an accompanying editorial, Drs Robert I Psaty (University of HAPPENING OFnational centre, Seattle) and Curt Furberg (Wake Timberland Body, Winston-Salem, NC) try Nissen
This is a part of article Rosiglitazone Increases MI and CV Death in Meta-Analysis Taken from "Buy Avandia Rosiglitazone" Information Blog